|
Congressional:
Senate HELP Committee Holds Markup, Advancing Two Health Care Bills
On Thursday, the Senate Health, Education, Labor, and Pensions (HELP) Committee held a markup on four bills, including two health care bills. The committee advanced two health care bills and deferred action on a third bill, the Charlotte Woodward Organ Transplant Discrimination Prevention Act (S. 1782). The Living Donor Protection Act of 2025 (S. 1552) passed in a 22-1 vote. The bill would prohibit insurers from denying or altering life, disability, or long-term care insurance policies based solely on an individual's status as a living organ donor, unless there are unique actuarial risks. The bill would also amend the Family and Medical Leave Act (FMLA) to include recovery from organ donation surgery as a serious health condition, allowing both private and federal employees to use FMLA leave. The Health Care Cybersecurity and Resiliency Act of 2025 (S. 3315) passed in a 22-1 vote, and would require the Secretary of Health and Human Services and the Director of the Cybersecurity and Infrastructure Security Agency to coordinate to improve cybersecurity in the health care and public health sectors. See all the bills and votes here.
Senate HELP Committee Holds Hearing on Casey Means Nomination to be Surgeon General
On Wednesday, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on the nomination of Dr. Casey Means to be Surgeon General. During the hearing, Means emphasized that her central mission would be to shift the U.S. from "reactive sick care to proactive health care" by focusing on the "root causes" of chronic disease, including ultra-processed foods and metabolic dysfunction. She defended her positions on vaccines and birth control as promoting informed consent and a more nuanced conversation between individuals and their doctors, and she committed to using the Surgeon General's platform to make healthy living more accessible and affordable. Democrats, alongside Chairman Bill Cassidy (R-LA), raised concerns about how Means would approach vaccine guidance. Means repeatedly stated that she believed vaccines save lives, but that every patient or parent must have a "thorough conversation with their doctor" before any medical intervention, including vaccines, to rebuild trust in public health. Read Mean’s testimony here.
House Ways & Means Health Subcommittee Holds Hearing on Health Care Workforce
On Tuesday, the House Ways and Means Health Subcommittee held a hearing on advancing the next generation of the health care workforce. During the hearing, there was bipartisan agreement on the need to address the nation's physician shortage, improve health care access in rural and underserved areas, and interest in formally authorizing and funding the Health Resources and Services Administration (HRSA) -administered Rural Residency Planning and Development (RRPD) Program, which provides startup grants for new rural residency programs. Republicans emphasized reforming Graduate Medical Education (GME) to address geographic disparities and physician shortages in rural areas, expressed concern that current GME funding mechanisms are outdated and benefit large urban hospitals over rural communities, and highlighted the need to integrate chronic disease prevention, nutrition, and technology into physician training. Democrats linked the workforce shortage to broader Republican policies, including healthcare funding cuts and limits on loans for professional degrees, making medical education unaffordable. Read Mehlman’s hearing summary here.
Senate Special Committee on Aging Holds Hearing on FDA Innovation
On Thursday, the Senate Special Committee on Aging held a hearing titled “From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation.” During the hearing, Republican members argued that more needs to be done to reduce regulatory burdens for companies developing rare-disease drugs. Committee Chair Rick Scott (R-FL) stated that FDA Commissioner Marty Makary is “working hard to fix long-standing problems at the FDA,” but expressed concern about what he described as “inaction and delays.” Democrats expressed concern that political influence was affecting scientific decision-making at the Food and Drug Administration (FDA). Ranking Member Kirsten Gillibrand (D-NY) stated, “We’ve seen a pattern of hesitation to use authorized flexibilities, limited communication with drug sponsors, failure to incorporate patient experience and real-world evidence reviews, and FDA shifting its regulatory position on trial design at the last minute, rejecting drug applications and requiring new clinical trials the sponsor may be unable to perform.” Read the opening statements and witness testimonies here.
House to Add Earmarks to Fiscal Year 2027 Labor-Health-Education Spending Bill
On Wednesday, House Appropriations Committee Chairman Tom Cole (R-OK) released guidance for Fiscal Year 2027 programmatic, language, and Community Project Funding requests. House members can seek funding for more projects in their districts in the next round of appropriations bills and can request earmarks in the Labor-HHS-Education bill. Cole wrote in a letter to colleagues that the new limit for Community Project Funding requests is 20 projects per Member, up from 15 previously. Earmark spending will remain capped at 1% of total discretionary spending, with 0.5% divided for each chamber. Read the press release here.
Notable Bills:
Senators Collins, Peters Introduce Bipartisan Bill to Improve Disease Management and Prevention
On Thursday, Senators Susan Collins (R-ME) and Gary Peters (D-MI) introduced the bipartisan Medical Nutrition Therapy Act. The legislation would expand Medicare beneficiaries’ access to Medical Nutrition Therapy (MNT) to treat obesity, diabetes, hypertension, dyslipidemia, and other chronic conditions. The bill would also allow more types of providers to refer patients to MNT, including nurse practitioners, physician assistants, clinical nurse specialists, and psychologists. Read the press release here and the bill here.
Executive Branch:
Trump Administration Announces Major Crackdown on Health Care Fraud
On Wednesday, Vice President J.D. Vance, Secretary of Health and Human Services (HHS) Robert F. Kennedy, Jr., and Administrator of the Centers for Medicare & Medicaid Services (CMS) Dr. Mehmet Oz announced new steps to reduce fraud in Medicare and Medicaid. The actions include deferring $259.5 million of quarterly federal Medicaid funding in Minnesota, a six-month nationwide moratorium on Medicare enrollment for new Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) suppliers, and a Request for Information (RFI) on additional ways the agency can tackle fraud prevention to help inform the development of a possible future rule under CMS’ Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative. Comments on the CRUSH RFI are due by March 20, 2026. Read the press release here.
President Trump Delivers State of the Union
On Tuesday, President Trump gave his first State of the Union address of his second term. During the address, health care received only brief attention in the 108-minute speech, which largely centered on immigration and tax policy. On health care, Trump renewed his call to Congress to codify most favored nation (MFN) prescription drug pricing and highlighted TrumpRx, a direct-to-consumer website featuring voluntary pricing agreements negotiated with five drugmakers. He additionally called for action on “The Great Healthcare Plan,” a legislative framework aimed at lowering costs, increasing price transparency, and reducing insurance premiums. Trump also criticized the Affordable Care Act (ACA), calling it the "Unaffordable Care Act" and emphasized his plan to return health insurance subsidies directly to Americans. See the address here.
In the Democratic response to Trump's speech, Virginia Governor Abigail Spanberger stated that congressional Republicans are "making it more difficult to see a doctor," and that rural health clinics are closing as a result of the One Big Beautiful Bill Act (OBBBA) passed last year. Read the remarks here.
FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases
On Monday, the Food and Drug Administration (FDA) issued draft guidance for sponsors seeking full approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety when randomized controlled trials are not feasible due to small patient populations. The draft guidance, issued by the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research, specifically discusses genome editing and RNA-based therapies such as antisense oligonucleotides, but leaves open the potential that this framework may apply to additional tailored therapeutics, provided they directly address the underlying specific cause of the disease. Read the press release here and draft guidance here.
CDC Principal Deputy Director, Ralph Abraham, Resigns
On Monday, the Centers for Disease Control and Prevention (CDC) announced that Dr. Ralph Abraham has stepped down as Principal Deputy Director, effective immediately due to “unforeseen family obligations.” Read the press release here.
|